Abstract X-linked adrenoleukodystrophy (ALD) is an inborn error of peroxisomal metabolism characterised by progressive demyelination of the central nervous system and by hypoadrenalism. The biochemical defect of ALD results in an impairment in degradation of very long chain fatty acids (VLCFA) with their accumulation in plasma and tissues. Many therapeutic approaches have been tried. Recently, a restricted diet and glycerol trioleatelerucic (GTOE) supplementation have shown normalisation of VLCFA plasma levels, although they are not effective in altering the clinical course of X-linked ALD.
chemical defect of ALD results in an impairment in degradation of very long chain fatty acids (VLCFA) with their accumulation in plasma and tissues. Many therapeutic approaches have been tried. Recently, a restricted diet and glycerol trioleatelerucic (GTOE) supplementation have shown normalisation of VLCFA plasma levels, although they are not effective in altering the clinical course of X-linked ALD.
The preliminary results are presented of a twelve month trial of immunomodulation by intravenous high-dose immunoglobulins in six patients, mean (SD) age 10-48 (2.8) affected by X-linked ALD, on VLCFA restricted diet plus GTOE supplementation therapy. Six patients aged 9*30 (1.5) with similar clinical characteristics and on the same restricted VLCFA regime of GTOIGTE therapy were studied as the control group.
After two months VLCFA levels fell to normal values and remained so for all patients throughout the study. These data show that immunoglobulins are not able to arrest the progression of the disease. The MRI and clinical symptoms deteriorated to the same extent in both groups. observed 12 patients affected by X-linked childhood and adolescent ALD between January 1991 and June 1993. The diagnosis was confirmed by measuring VLCFA in plasma considering the absolute amount of C26:0 and C26/C22 ratio, using a previously described method. 4 The patients were randomly subdivided into two groups according to their age and grade of neurological status (Kurtzke score less than or equal to 5)9: Group 1-Six patients aged between 7-9 to 14 years were given VLCFA restricted diet plus GTOE oil supplementation therapy, plus intravenous gammaglobulin therapy. Group 2-Six patients aged between seven to 12-6 years were given VLCFA restricted diet plus GTOE oil supplementation therapy.
All patients were admitted to the Department of Endocrinology of the Bambino Gesu Hospital under an institutionally approved protocol for the study. Written informed consent was obtained from all subjects and/or their guardians.
Mean (SD) results of the patients in the study. Patients 1-6 (group 1) on IG + diet therapy; patients 7-12 (group 2) diet alone Kurtzke EDSS score (Kurtzke score): 3 0 mild disability; 3-5 moderate disability; 4 0 self-sufficient for up to 12 hours; 4-5 require minimal assistance, has some limits on activity but able to work a full day; 5-0 severe disability, cannot perform full day's activity, but ambulatory without aid; 5-5 severe disability precluding full day's activities, walks about 100 metres; 6 requires unilateral assistance to walk 100 metres; 6-5 requires bilateral assistance for walking 20 metres; 7 walks less than 5 metres and essentially restricted to a wheelchair; 7-5 restricted to a wheelchair; 8 restricted to bed or chair; 9 vegetative state. Change of 0 5 was considered stable condition.
CLINICAL EVALUATION
The patients had a standard physical examination, electrocardiography, echocardiography, biochemistry comprising electrolytes, liver-enzyme, platelet leukocyte counts on admission and every three months. VLCFA and C:26/C:22 ratios were assessed at admission and every three months. 
